4 Results Found

Advanced Search

Select all

Results per page

Select all

Article

3 Citations

2,348 Views

17 Pages

Increased In Vivo Exposure of N-(4-Hydroxyphenyl) Retinamide (4-HPR) to Achieve Plasma Concentrations Effective against Dengue Virus

Alexander J. Martin,
David M. Shackleford,
Susan A. Charman,
Kylie M. Wagstaff,
Christopher J. H. Porter and
David A. Jans

Pharmaceutics2023, 15(7), 1974;https://doi.org/10.3390/pharmaceutics15071974

18 July 2023

N-(4-hydroxyphenyl) retinamide (4-HPR, or fenretinide) has promising in vitro and in vivo antiviral activity against a range of flaviviruses and an established safety record, but there are challenges to its clinical use. This study evaluated the in v...

Full Article

Article

2,637 Views

9 Pages

One-Step, Low-Cost, Operator-Friendly, and Scalable Procedure to Synthetize Highly Pure N-(4-ethoxyphenyl)-retinamide in Quantitative Yield without Purification Work-Up

Silvana Alfei and
Guendalina Zuccari

Molecules2022, 27(11), 3632;https://doi.org/10.3390/molecules27113632

6 June 2022

It is widely reported that N-(4-hydroxyphenyl)-retinamide or fenretinide (4-HPR), which is a synthetic amide of all-trans-retinoic acid (ATRA), inhibits in vitro several types of tumors, including cancer cell lines resistant to ATRA, at 1–10 &m...

Full Article

Review

16 Citations

4,179 Views

18 Pages

Fenretinide in Cancer and Neurological Disease: A Two-Face Janus Molecule

Rosa Luisa Potenza,
Pietro Lodeserto and
Isabella Orienti

Int. J. Mol. Sci.2022, 23(13), 7426;https://doi.org/10.3390/ijms23137426

4 July 2022

Recently, several chemotherapeutic drugs have been repositioned in neurological diseases, based on common biological backgrounds and the inverse comorbidity between cancer and neurodegenerative diseases. Fenretinide (all-trans-N-(4-hydroxyphenyl) ret...

Full Article

Review

24 Citations

6,956 Views

15 Pages

Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment in COVID-19

Isabella Orienti,
Giovanna Angela Gentilomi and
Giovanna Farruggia

Int. J. Mol. Sci.2020, 21(11), 3812;https://doi.org/10.3390/ijms21113812

27 May 2020

At present, there is no vaccine or effective standard treatment for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection (or coronavirus disease-19 (COVID-19)), which frequently leads to lethal pulmonary inflammatory responses. COVI...

Full Article